非血缘脐血移植治疗高体重成人恶性血液病的临床研究

doi:10.3969/j.issn.1671-2587.2026.03.019

临床输血与检验 ›› 2026, Vol. 28 ›› Issue (3): 418-424.DOI: 10.3969/j.issn.1671-2587.2026.03.019

非血缘脐血移植治疗高体重成人恶性血液病的临床研究

姜开爽, 范倩, 强萍, 耿良权, 刘会兰

中国科学技术大学附属第一医院（安徽省立医院）血液科,安徽合肥 230000

收稿日期:2025-12-10 出版日期:2026-06-20 发布日期:2026-07-07
通讯作者: 刘会兰,主要从事造血干细胞移植研究,（E-mail）huilanl@ustc.edu.cn。
作者简介:姜开爽,主要从事血液病研究,（E-mail）j15546063165@163.com。

Clinical Study on Unrelated Umbilical Cord Blood Transplantation for High-body-weight Adult Patients with Hematological Malignancies

JIANG Kaishuang, FAN Qian, QIANG Ping, GENG Liangquan, LIU Huilan

Department of Haematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230000

Received:2025-12-10 Online:2026-06-20 Published:2026-07-07

摘要/Abstract

摘要： 目的评估非血缘脐血移植（UCBT）治疗高体重成人恶性血液病患者的疗效与安全性。方法回顾分析2018年1月—2024年9月在单中心接受单份UCBT的121例高体重（≥70 kg）恶性血液病患者的临床结果。结果与低体重组（<70 kg）相比,高体重组患者回输总有核细胞数显著减少（P<0.01）,但植入前综合征发生率明显增高[80.83% vs. 69.42%（P<0.01）]。两组在移植后其他并发症及生存方面均无差异。结论 UCBT是高体重恶性血液病患者安全有效的治疗方法。

关键词: 脐带血移植, 非血缘, 高体重, 恶性血液病

Abstract: Objective To evaluate the efficacy and safety of unrelated umbilical cord blood transplantation (UCBT) in the treatment of adult patients with hematological malignancies who have a high body weight. Methods A retrospective analysis was conducted on the clinical outcomes of 121 adult patients with hematological malignancies. All patients had a high body weight (≥70 kg) and underwent single-unit UCBT at a single center between January 2018 and September 2024. Results Compared with the low body weight group (<70 kg), the total number of nucleated cells infused was significantly lower in the high body weight group (P<0.01). However, the incidence of pre-engraftment syndrome was significantly higher in the high body weight group [80.83% vs. 69.42% (P<0.01)]. There were no significant differences between the two groups in terms of other post-transplant complications or survival outcomes. Conclusion UCBT is a safe and effective treatment option for adult patients with hematological malignancies who have a high body weight.

Key words: Umbilical cord blood transplantation, Unrelated, High body weight, Hematological malignancies

中图分类号:

R457.7

姜开爽, 范倩, 强萍, 耿良权, 刘会兰. 非血缘脐血移植治疗高体重成人恶性血液病的临床研究[J]. 临床输血与检验, 2026, 28(3): 418-424.

JIANG Kaishuang, FAN Qian, QIANG Ping, GENG Liangquan, LIU Huilan. Clinical Study on Unrelated Umbilical Cord Blood Transplantation for High-body-weight Adult Patients with Hematological Malignancies[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(3): 418-424.

参考文献

[1] Majhail N S,Farnia S H,Carpenter P A,et al.Indications for autologous and allogeneic hematopoietic cell transplantation:guidelines from the American society for blood and marrow transplantation[J]. Biol Blood Marrow Transplant,2015,21(11):1863-1869.
[2] Lee C J,Savani B N,Mohty M,et al.Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia:a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation[J]. Haematologica, 2017,102(11):1810-1822.
[3] Zhu X Y,Tang B L,Sun Z M.Umbilical cord blood transplantation:Still growing and improving[J]. Stem Cells Transl Med,2021,10(Suppl 2):S62-S74.
[4] Luznik L,O'Donnell P V,Symons H J,et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose,posttransplantation cyclophosphamide[J].Biol Blood Marrow Transplant, 2008,14(6):641-650.
[5] Xu L P,Lu P H,Wu D P,et al.Hematopoietic stem cell transplantation activity in China 2022—2023. The proportions of peripheral blood for stem cell source continue to grow:a report from the Chinese Blood and Marrow Transplantation Registry Group[J]. Bone Marrow Transplant,2024,59(12):1726-1734.
[6] Barker JN, Krepski TP, DeFor TE,et al. Searching for unrelated donor hematopoietic stem cells:availability and speed of umbilical cord blood versus bone marrow[J].Biol Blood Marrow Transplant,2002,8(5):257-260.
[7] Yamamoto H.Single cord blood transplantation in Japan; expanding the possibilities of CBT[J]. Int J Hematol, 2019,110(1):39-49.
[8] Mehta RS, Dave H, Bollard CM, et al.Engineering cord blood to improve engraftment after cord blood transplant[J]. Stem Cell Investig,2017,4(6):41.
[9] Jin L L,Sun Z M,Liu H L,et al.Inflammatory monocytes promote pre-engraftment syndrome and tocilizumab can therapeutically limit pathology in patients[J]. Nat Commun,2021,12(1):4137.
[10] Lee Y H,Rah W J.Pre-engraftment syndrome:clinical significance and pathophysiology[J]. Blood Res,2016, 51(3):152-154.
[11] Sakurai M,Kataoka K,Mizuno K,et al.Risk factors for and impact of pre-engraftment syndrome on outcomes following single-unit cord blood transplantation in adults[J]. Am J Hematol,2025,100(12):2248-2260.
[12] Wikstrom M E,Fleming P,Kuns R D,et al.Acute GVHD results in a severe DC defect that prevents T-cell priming and leads to fulminant cytomegalovirus disease in mice[J]. Blood,2015,126(12):1503-1514.
[13] Prösch S,Priemer C,Höflich C,et al.Proteasome inhibitors:a novel tool to suppress human cytomegalovirus replication and virus-induced immune modulation[J]. Antivir Ther,2003,8(6):555-567.
[14] AlQahtani H Y,AlSuhebany N,Alowais S A,et al. Characterization of recurrent cytomegalovirus reactivations post allogenic stem cell transplantation in a population with high seropositivity[J]. Virol J,2024, 21(1):149.
[15] Melendez-Munoz R,Marchalik R,Jerussi T,et al.Cytomegalovirus infection incidence and risk factors across diverse hematopoietic cell transplantation platforms using a standardized monitoring and treatment approach:a comprehensive evaluation from a single institution[J]. Biol Blood Marrow Transplant,2019, 25(3):577-586.
[16] Elmariah H,Brunstein C G,Bejanyan N.Immune reconstitution after haploidentical donor and umbilical cord blood allogeneic hematopoietic cell transplantation[J]. Life (Basel),2021,11(2):102.

非血缘脐血移植治疗高体重成人恶性血液病的临床研究

Clinical Study on Unrelated Umbilical Cord Blood Transplantation for High-body-weight Adult Patients with Hematological Malignancies

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 6

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	马婷, 范亮峰, 李婧薇, 孙杨, 杨江存, 向东. 脐带血移植后并发自身免疫性溶血性贫血及迟发性输血反应一例分析^*[J]. 临床输血与检验, 2025, 27(6): 835-841.
[2]	张咏, 耿良权, 强萍, 范倩, 刘会兰. ABO血型主要及双向不合对757例非血缘脐血移植结局的影响分析^*[J]. 临床输血与检验, 2025, 27(4): 518-525.
[3]	沈汉影, 汤宝林, 强萍. 恶性血液病患者侵袭性真菌病的研究进展[J]. 临床输血与检验, 2025, 27(2): 274-282.
[4]	王慧茹, 刘会兰. 非血缘脐血移植术后患者输血情况相关影响因素分析^*[J]. 临床输血与检验, 2021, 23(2): 162-166.
[5]	吴月, 朱小玉, 刘会兰, 宋闿迪, 汤宝林, 孙自敏. 强化清髓单份非血缘脐血移植治疗FLT3-ITD突变阳性急性髓系白血病疗效观察^*[J]. 临床输血与检验, 2020, 22(6): 627-632.
[6]	范维, 周海洋. 脐带血临床应用研究进展[J]. 临床输血与检验, 2020, 22(6): 664-669.